HC Wainwright Cuts Earnings Estimates for Oncolytics Biotech

Oncolytics Biotech Inc. (TSE:ONC) – Research analysts at HC Wainwright cut their FY2028 earnings per share estimates for Oncolytics Biotech in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.57 for the year, down from their previous forecast of $0.60. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2029 earnings at $1.06 EPS.

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

ONC opened at C$0.91 on Wednesday. The company has a 50 day simple moving average of C$1.10 and a two-hundred day simple moving average of C$1.30. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The firm has a market cap of C$70.14 million, a P/E ratio of -2.54 and a beta of 1.35. Oncolytics Biotech has a 1-year low of C$0.86 and a 1-year high of C$2.08.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.